37 results about "Castration" patented technology

This invention relates to talazoparib, or a pharmaceutically acceptable salt thereof, in combination with enzalutamide, or a pharmaceutically acceptable salt thereof, for the treatment of homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer and methods of increasing overall survival thereof.

The invention provides a dalotamide monophosphate compound shown as a formula I or a pharmaceutically acceptable salt thereof, and n is an integer of 1-3, preferably an integer of 1-2. The compound provided by the invention can be used for preparing medicines for treating adult patients with non-metastatic castration-resistant prostate cancer with high metastasis risk.

The invention belongs to the technical field of cancer treatment, and discloses a method for inhibiting castration-resistant prostate cancer proliferation and metastasis by promoting collagen degradation through targeting ADAMTS1. According to the method, ADAMTS1 is determined to be a mechanism key point for linking epigenetic reprogramming with biomechanical microenvironment destruction. The ADAMTS1 is reactivated to degrade a collagen-rich matrix, the FAK / MAPK mechanical transduction signaling pathway is inhibited, and the epithelial-mesenchymal transition (EMT) is reversed. The strategy not only achieves more than 90% of tumor inhibition effect, but also exhausts immunosuppressive macrophages and regulatory T cells to reverse immunosuppression by enhancing toxic CD8 + T cell infiltration. The research determines that epigenetic-ECM coevolution is a symbolic feature of CRPC, and provides a reasonably designed combination therapy for treating castration-resistant prostate cancer.

Methods of treating non-metastatic castration-resistant prostate cancer in a subject having severe liver damage are provided.SOLUTION: Provided are methods of treating non-metastatic castration-resistant prostate cancer in a subject with severe hepatic impairment with an androgen receptor inhibitor comprising 4 - [7 - (6-cyano-5-trifluoromethylpyridin-3-yl) - 8-oxo-6-thioxo-5, 7-diazaspiro [3.4] oct-5-yl] - 2-fluoro-N-methylbenzamide (apalutamide).SELECTED DRAWING: None

This is a method for treating prostate cancer. Specifically, it involves the use of the compound shown in Formula I or a pharmaceutically acceptable salt thereof in the manufacture of a drug for treating metastatic castration-resistant prostate cancer. [Formula 1] JPEG2026521901000005.jpg32155

The invention relates to the technical field of biological medicine, and particularly discloses application of nefenavir. Nefinavir is used for preparing a medicine for treating or preventing castration-resistant prostate cancer, and the medicine can specifically up-regulate expression of DHCR7, induce DNA damage of tumor cells and activate a cell cycle arrest pathway mediated by periodic protein of the cells so as to inhibit key biological processes such as proliferation of the tumor cells, cholesterol metabolism and the like; especially, formation and amplification of multinuclear giant cells in castration-resistant prostate cancer can be effectively inhibited by up-regulating expression of DHCR7, so that malignant progression of multinuclear giant cell mediated tumors and treatment of drug resistance are blocked. Finally, the castration-resistant prostate cancer is prevented and treated, and the technical bottlenecks that an existing castration-resistant prostate cancer treatment means is limited in curative effect, and the drug resistance and metastasis capability mediated by multinuclear giant cells are difficult to inhibit in a targeted manner are solved.

The application belongs to the technical field of biological medicine, and discloses application of a MYLK3 gene inhibitor in preparation of a drug for treating castration-resistant prostate cancer. The biological function of MYLK3 in prostate cancer is confirmed for the first time, an intervention means with the gene as a target point is provided, and it is confirmed that the MYLK3 inhibitor can improve the sensitivity of castration-resistant prostate cancer to androgen receptor antagonists. A gene therapy drug with the human MYLK3 gene as a treatment target point is specially provided, which is suitable for the treatment of prostate cancer (especially castration-resistant prostate cancer), and can also be combined with other targeted drugs to improve the treatment effect. By designing a reasonable RNAi target sequence for the target gene, a retrovirus vector plasmid containing the target sequence is successfully constructed, which has a significant inhibitory effect on the proliferation ability of prostate cancer cells, and significantly increases the sensitivity of prostate cancer cells to AR antagonists.

The present invention relates to methods for predicting the progression of prostate cancer, specifically metastatic castration-resistant prostate cancer (mCRPC), in an individual. The invention employs gene expression profiling combined with predictive modeling to assess the likelihood of overall survival and biochemical recurrence following treatment.

The application discloses a compound based on a PROTAC strategy and a preparation method, a pharmaceutical composition and application thereof, discloses a compound with AR / AR-V7 protein degradation activity and a preparation method, a pharmaceutical composition and application thereof. The structure of the compound is as shown in the formula I. The compound can effectively degrade AR / AR-V7 proteins in vivo and in vitro, has a significant antitumor effect, has no obvious toxic side effects, and can be used for treating castration-resistant prostate cancer. The preparation method of the compound is simple and easy to operate, and is beneficial to structural expansion.

The present disclosure discloses application of PRDX5 and GPX4 genes in preparation of drugs for castration-resistant prostate cancer and belongs to the technical field of biological medicines. The present disclosure proposes that silencing or interfering with the expression of the PRDX5 and / or GPX4 genes can be used in the treatment or adjuvant treatment of castration-resistant prostate cancer. The present disclosure proposes for the first time a new strategy for preparing the drugs for the treatment of CRPC using siRNA in combination with an androgen receptor antagonist. The pharmaceutical composition comprising siRNA in combination with an androgen receptor antagonist according to the present disclosure can be used for the treatment of castration-resistant prostate cancer and significantly improves the inhibitory effect of enzalutamide on castration-resistant prostate cancer, which provides the basis for the design and clinical application of nucleic acid drugs with important clinical therapeutic significance.

Described herein are radiopharmaceuticals for the treatment of PSMA-expressing cancers, and methods and / or uses of such compounds for the treatment of PSMA-expressing cancers, such as, for example, metastatic castration-resistant prostate cancer.

There is provided methods for insect control, including controlling myiasis, in animals by affixing to the animal an elastomeric band having infused or contained within an insecticide, an insect repellent, lidocaine, or any combination thereof. The insect control may be a dual-mode control and may be in respect of existing or impending open wounds, including open wounds caused by castration, tail docking, umbilical cord ligation, or dehorning of an animal. There is also provided methods for castration, docking, umbilical cord ligation, or dehorning of an animal with concurrent insect control. Also provided are elastomeric bands for insect control and methods for preparing such elastomeric bands.

The present invention relates to a dosage regimen of a tevirelix-TFA composition for the treatment of prostate cancer. The dosing regimen comprises a loading dose of 360 mg SC and 180 mg IM tevirelix-TFA composition, and a low maintenance dose (360 mg SC) of the tevirelix-TFA composition once every six weeks starting from the 28th day. Thus, the dosing regimen according to the present invention provides an improved dosing regimen in which a castration rate of > = 95% is obtained over a treatment period of 52 weeks, and less side effects and adverse events, thereby providing an optimized response / side effect relationship.

A method for castration of animals. A non-surgical method for castration of animals which includes administering GnRH-I-AP205 virus-like particle subunit vaccine to animals. The required dose is very small, and 0.25 ml / animal will work.

The present disclosure relates to a method of treating prostate cancer, including prostate cancer comprising at least one somatic AR tumor mutation in a subject, e.g., metastatic prostate cancer, castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, progressive metastatic castration-resistant prostate cancer, castration-sensitive prostate cancer, metastatic castration-sensitive prostate cancer, novel hormonal agent (NHA)-naive prostate cancer, NHA-naive metastatic prostate cancer, NHA-naive castration-resistant prostate cancer, NHA-naive castration-sensitive prostate cancer, NHA-naive metastatic castration-resistant prostate cancer, and NHA-naive metastatic castration-sensitive prostate cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof. JPEG2026500894000245.jpg50170

The embodiment of the invention discloses an LRG1 nano antibody and application thereof. The LRG1 nano antibody provided by the invention has the advantages of simple structure, low cost, high affinity, good thermal stability, high tissue penetrability and epitope accessibility, low immunogenicity and the like, can be used for preparing diagnostic reagents and therapeutic drugs for castration resistant prostate cancer (CRPC), provides new technology and drug support for accurate diagnosis and treatment of CRPC, and has a relatively good application prospect.

The invention belongs to the technical field of biological medicines, and discloses application of an MYLK3 gene inhibitor in preparation of a medicine for treating castration-resistant prostate cancer. The biological function of the MYLK3 in the prostatic cancer is confirmed for the first time, an intervention means taking the MYLK3 as a target spot is provided, and it is clear that the MYLK3 inhibitor can improve the sensitivity of the castration-resistant prostatic cancer to an androgen receptor antagonist. The invention particularly provides a gene therapeutic drug taking the human MYLK3 gene as a therapeutic target, which is suitable for treating prostatic cancer (especially castration-resistant prostatic cancer) and can also be used in combination with other targeted drugs to improve the therapeutic effect. A reasonable RNAi target sequence is designed for a target gene, a retrovirus vector plasmid containing the target sequence is successfully constructed, the retrovirus vector plasmid has a remarkable inhibition effect on the proliferation capacity of prostate cancer cells, and meanwhile, the sensitivity of the prostate cancer cells to AR antagonists is remarkably improved.

The present invention discloses the use of stachyose in the preparation of a drug for treating castration-resistant prostate cancer, which belongs to the field of biomedicine. The present invention is the first to propose a new strategy for combining stachyose with androgen receptor antagonists to prepare a drug for treating CRPC, and conducts multifaceted and multi-stage validation research. The pharmaceutical composition of the present invention combining stachyose with androgen receptor can be used to treat castration-resistant prostate cancer, which can significantly improve the inhibitory effect of enzalutamide on castration-resistant prostate cancer, and the application of natural compounds to late-stage cancer is of great significance in clinical treatment.

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quindoline (or similar) structure which function as stabilizers of G-quadruplex (G4) formation, and their use as therapeutics for the treatment of cancer (e.g., castration-resistant prostate cancer), and other conditions mediated by G4 stabilization.

The present disclosure relates to a pharmaceutical product having at least one batch indication, wherein the pharmaceutical product comprises niraparib and abiraterone acetate.

The invention belongs to the technical field of cancer treatment, and discloses an application of an AR-DHCR7-7-DHC axis in castration resistant prostate cancer enzalutamide resistance. According to the application disclosed by the invention, the effect of 7-DHC in the drug resistance of enzalutamide is explored by combining single-cell multi-omics analysis, metabolic spectrum analysis and functional research. By illustrating the action mechanism of the AR-DHCR7-7-DHC axis, the research reveals how a steroid intermediate regulates mitochondrial apoptosis and an immunosuppressive tumor microenvironment, and provides an intervention approach with clinical transformation potential, namely inhibiting DHCR7-to block the drug-resistant pathway. These achievements not only deepen the understanding of castration resistant prostate cancer (CRPC) metabolic heterogeneity, but also provide a biomarker-based framework for using existing therapies to combat fatal therapeutic resistance.

The invention discloses a gene marker combination for predicting the curative effect of abiraterone in metastatic castration resistant prostate cancer (mCRPC). The gene marker combination comprises 16 genes, namely HDAC2, TP53, GEN1, FOXA1, ATR, MUTYH, SPOP, BRCA2, ATM, PALB2, RB1, CDK12, BARD1, PTEN, NCOR2 and MLH1. The invention further discloses an mCRPC abiraterone curative effect prediction model based on the marker combination and a construction method of the mCRPC abiraterone curative effect prediction model. According to the method, mCRPC gene markers highly related to abiraterone treatment response are screened based on detection data of related genes of prostate cancer in combination with clinical abiraterone treatment effect results, and an abiraterone treatment effect prediction model is constructed based on the markers, so that personalized prediction of the treatment effect of an mCRPC patient using abiraterone treatment is realized, and the treatment effect of the patient is improved. And an effective reference can be provided for accurate medication.

The invention relates to the field of therapeutic antibodies for the treatment of a subject with castration-resistant prostate cancer. More in particular it relates to treating castration-resistant prostate cancer using a bispecific antibody that comprises an antigen binding site that can bind an extracellular part of ERBB2 and an antigen binding site that can bind an extracellular part of ERBB3. Also, it relates to treating castration-resistant prostate cancer using an antibody that comprises an antigen binding site that can bind an extracellular part of ERBB3. The invention also relates to treating castration-resistant prostate cancer using a combination of one of said antibodies and an androgen receptor axis-targeting agent.

The application discloses a novel vaccine suitable for lipid-lowering and blood sugar-lowering castration of multiple species, a preparation method and application thereof, and is related to one or more combinations of a YETVKVPGCAHHADSL fragment of pigs, cattle, sheep, alpacas and horses, a YETVRVPGCARHADSL fragment of dogs and minks, a YPVATECHCGK fragment of pigs, cattle, sheep, alpacas, cats, rabbits and mice, a CDSDSTDCTVRGLGP fragment of humans, pigs, cattle, sheep, alpacas, dogs, giant pandas, rabbits and mice, and a CDSDSTDCTVQGLGP fragment of cats, tigers and lions, and a sequence with a homology of more than 70% to any one of the fragments. The protein vaccine can be effectively applied to treat diseases such as obesity, hyperlipidemia and diabetes caused by ovarian dysfunction, has pet and animal sterilization effects, can treat postmenopausal women or animals and pets that have undergone sterilization or castration surgery, and diseases such as obesity, hyperlipidemia and hyperglycemia caused by ovarian dysfunction, and has a good popularization prospect and medical economic value.

Methods of treating prostate cancer. Specifically, the invention relates to an application of a compound shown as a formula I or a pharmaceutically acceptable salt thereof in preparation of a medicine for treating metastatic castration-resistant prostate cancer.

The present disclosure relates to the treatment of (a) biochemical recurrence of nonmetastatic castration-sensitive prostate cancer, (b) localized prostate cancer, or (c) metastatic hormone-sensitive prostate cancer with an anti-STEAP1 antigen binding protein.

The present invention relates to a pharmaceutical composition comprising a solid dispersion of apalutamide and hydroxypropyl methylcellulose phthalate, wherein the solid dispersion is obtained by the spray-drying process. The invention further relates to the use of said pharmaceutical composition as a medicament in the treatment of non-metastatic castration-resistant prostate cancer and hormone-sensitive prostate cancer.

The subject matter described herein relates to a method of treating or preventing prostate cancer in a subject in need thereof, the method comprising modulating the expression of a first component of an intrinsic androgen signaling pathway and modulating the expression of a second component of an extrinsic androgen signaling pathway.